Suppr超能文献

生物增强方法可能是 ACL 关节镜下初次修复的可行选择 - 系统评价。

Biological enhancement methods may be a viable option for ACL arthroscopic primary repair - A systematic review.

机构信息

Department of Sports Medicine, Beijing Jishuitan Hospital, No. 31, Xinjiekou East Street, 10035 Beijing, China.

Department of Sports Medicine, Beijing Jishuitan Hospital, No. 31, Xinjiekou East Street, 10035 Beijing, China.

出版信息

Orthop Traumatol Surg Res. 2022 May;108(3):103227. doi: 10.1016/j.otsr.2022.103227. Epub 2022 Feb 2.

Abstract

BACKGROUND

Bioactive factors combined with advanced anterior cruciate ligament (ACL) primary repair technology have been used to treat ACL repairs. The current review was conducted to identify whether biological enhancement could enable superior clinical outcome, including side-to-side difference, failure rate, reoperation rate and subjective scores.

HYPOTHESIS

The implementation of ACL primary repair with biological enhancement will provide better clinical outcomes in terms of side-to-side differences, failure rate, reoperation rate and subjective scores than ACL primary repair alone.

MATERIALS AND METHODS

A systematic literature review was performed following PRISMA guidelines by searching all studies reporting outcomes of arthroscopic primary repair with or without biological augmentation published until April 19, 2020, in Medline, PubMed, Embase and the Cochrane Library. Primary metrics were side-to-side differences, failure rate and reoperation rate, as well as measurements of patient-reported outcomes at the last follow-up.

RESULTS

A total of 20 studies were finally included in this work, of which 3 were Grade I (15%), 3 studies were Grade III (15%), and 14 studies were Grade IV (70%) in terms of the level of evidence. There were 729 patients with a mean age of 30 (range: 8-68) years, and the mean follow-up period of which was 38 (range: 3-122) months. At the final follow-up, the postoperative side-to-side differences (the proportion of patients with a side-to-side difference less than 3mm) and patient-report outcomes were significantly better in the biological enhancement group. Nevertheless, there were no significant differences between the two groups in the rate of surgical failure, the rate of revision, or the positive Lachman test or pivot shift test.

CONCLUSION

Biologically enhanced arthroscopic ACL primary repair was superior to ACL primary repair alone in terms of postoperative side-to-side differences (proportion of patients with a side-to-side difference less than 3mm) and patient-reported outcomes. Thus, biologically enhanced arthroscopic ACL primary repair can be preferentially recommended over ACL arthroscopic primary repair alone.

LEVEL OF EVIDENCE

IV, systematic review.

摘要

背景

生物活性因子结合先进的前交叉韧带(ACL)初次修复技术已被用于 ACL 修复。本综述旨在确定生物增强是否能带来更优的临床结果,包括膝关节双侧差值、失败率、再次手术率和主观评分。

假设

与单纯 ACL 初次修复相比,采用 ACL 初次修复联合生物增强可在膝关节双侧差值、失败率、再次手术率和主观评分方面提供更好的临床结果。

材料和方法

按照 PRISMA 指南进行系统文献综述,检索截至 2020 年 4 月 19 日 Medline、PubMed、Embase 和 Cochrane 图书馆中所有报告关节镜下 ACL 初次修复联合或不联合生物增强的研究,分析术后膝关节双侧差值、失败率和再次手术率以及末次随访时患者报告的结局测量指标。

结果

最终共有 20 项研究纳入本研究,其中 3 项为Ⅰ级(15%),3 项为Ⅲ级(15%),14 项为Ⅳ级(70%)。共纳入 729 例患者,平均年龄 30 岁(8-68 岁),平均随访时间 38 个月(3-122 个月)。末次随访时,生物增强组术后膝关节双侧差值(双侧差值<3mm 的患者比例)和患者报告结局明显优于单纯 ACL 修复组。然而,两组在手术失败率、再次手术率、Lachman 试验或前抽屉试验阳性率方面无显著差异。

结论

与单纯 ACL 初次修复相比,生物增强关节镜下 ACL 初次修复在术后膝关节双侧差值(双侧差值<3mm 的患者比例)和患者报告结局方面更具优势。因此,生物增强关节镜下 ACL 初次修复可优先推荐用于单纯 ACL 关节镜下初次修复。

证据等级

IV,系统评价。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验